| 前收盘价格 | 0.155 |
| 收盘价格 | 0.150 |
| 成交量 | 16,345,517 |
| 平均成交量 (3个月) | 8,802,220 |
| 市值 | 285,745,696 |
| 价格/销量 (P/S) | 52.88 |
| 股市价格/股市净资产 (P/B) | 3.98 |
| 52周波幅 | |
| 利润日期 | 29 Jul 2025 - 4 Aug 2025 |
| 营业利益率 (TTM) | -8,467.07% |
| 稀释每股收益 (EPS TTM) | -0.020 |
| 季度收入增长率 (YOY) | -0.10% |
| 总债务/股东权益 (D/E MRQ) | 0.94% |
| 流动比率 (MRQ) | 10.63 |
| 营业现金流 (OCF TTM) | -34.93 M |
| 杠杆自由现金流 (LFCF TTM) | -26.79 M |
| 资产报酬率 (ROA TTM) | -34.35% |
| 股东权益报酬率 (ROE TTM) | -56.99% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | BOTANIX FPO [BOT] | - | - |
AIStockmoo 评分
2.1
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 2.13 |
|
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 12.29% |
| 机构持股比例 | 23.43% |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合